Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Peripheral Arterial Disease: Features

Dr Ramon Varcoe
ISET 2023
Results From the SWING Study; New Drug-Coated Balloons BTK; Endografts for AAA
02/27/2023
Dr. Ramon Varcoe discusses his ISET 2023 presentations on results from the SWING study, new drug-coated balloons BTK, and endografts for AAA.
Dr. Ramon Varcoe discusses his ISET 2023 presentations on results from the SWING study, new drug-coated balloons BTK, and endografts for AAA.
Dr. Ramon Varcoe discusses his...
02/27/2023
Vascular Disease Management
Dr Brian DeRubertis
ISET 2023
Scaffolds for the BTK Space: Current Data Landscape
02/27/2023
Watch Dr. Brian DeRubertis discuss his presentation at ISET 2023 on scaffolds for the below-the-knee-space.
Watch Dr. Brian DeRubertis discuss his presentation at ISET 2023 on scaffolds for the below-the-knee-space.
Watch Dr. Brian DeRubertis...
02/27/2023
Vascular Disease Management
Dr Brodmann
ISET 2023
What We Have Learned From Limus Devices in Europe
02/27/2023
Dr. Marianne Brodmann from the Medical University of Graz, Austria, discusses her ISET 2023 presentation on what we can learn from European use of limus-coated devices.
Dr. Marianne Brodmann from the Medical University of Graz, Austria, discusses her ISET 2023 presentation on what we can learn from European use of limus-coated devices.
Dr. Marianne Brodmann from the...
02/27/2023
Vascular Disease Management
Dr Secemsky
ISET 2023
How IVUS Improves Clinical Outcomes; BELONG Study; Interpretation of BEST-CLI
02/23/2023
Dr. Eric Secemsky, from Beth Israel Deaconess Medical Center in Boston, Massachusetts, discusses his presentations from ISET 2023.
Dr. Eric Secemsky, from Beth Israel Deaconess Medical Center in Boston, Massachusetts, discusses his presentations from ISET 2023.
Dr. Eric Secemsky, from Beth...
02/23/2023
Vascular Disease Management
Dr Daniel Clair
ISET 2023
Endograft Durability 30 Years Later; Results From the PROMISE II U.S. Pivotal Trial
02/23/2023
In this video from ISET 2023, Dr. Daniel Clair from Vanderbilt University Medical Center in Nashville, Tennessee, discusses his presentations on endograft durability and results of the PROMISE II trial.
In this video from ISET 2023, Dr. Daniel Clair from Vanderbilt University Medical Center in Nashville, Tennessee, discusses his presentations on endograft durability and results of the PROMISE II trial.
In this video from ISET 2023,...
02/23/2023
Vascular Disease Management
Pharmacological Treatment of PAD Patients
ISET 2023
Pharmacological Treatment of PAD Patients: A Case-Based Discussion
02/17/2023
Ian Del Conde-Pozzi, MD, John Rundback, MD, and Eric Secemsky, MD, discuss this important topic.
Ian Del Conde-Pozzi, MD, John Rundback, MD, and Eric Secemsky, MD, discuss this important topic.
Ian Del Conde-Pozzi, MD, John...
02/17/2023
Vascular Disease Management
Original Research
Examining Sex-Based Differences Among Individuals With Peripheral Arterial Disease in Southwest Louisiana: A Secondary Data Analysis
02/16/2023
Exploring the relationship between sex and determinants of PAD and symptom severity, treatments offered, and outcomes.
Exploring the relationship between sex and determinants of PAD and symptom severity, treatments offered, and outcomes.
Exploring the relationship...
02/16/2023
Vascular Disease Management
Interview
Two-Year Results of the ILLUMINA Study: An Interview With Andrea Kahlberg, MD
01/19/2023
VDM speaks with Dr. Andrea Kahlberg to discuss the 2-year results of the ILLUMINA study.
VDM speaks with Dr. Andrea Kahlberg to discuss the 2-year results of the ILLUMINA study.
VDM speaks with Dr. Andrea...
01/19/2023
Vascular Disease Management
Dr Varcoe
ISET 2023
12-Month Results From the SWING Multicentre Study: A Novel Sirolimus-Coated Balloon for Use Below-the-Knee
01/18/2023
Dr. Ramon Varcoe presented results from SWING, a prospective, multicenter, single-arm, feasibility study that evaluated the safety and performance of the Sundance DCB in 35 patients at 8 test sites in Australia, New Zealand, and Europe.
Dr. Ramon Varcoe presented results from SWING, a prospective, multicenter, single-arm, feasibility study that evaluated the safety and performance of the Sundance DCB in 35 patients at 8 test sites in Australia, New Zealand, and Europe.
Dr. Ramon Varcoe presented...
01/18/2023
Vascular Disease Management
Dr George Adams
ISET 2023
LIBERTY Real-World Evidence on CLTI and Diabetic Patients
01/17/2023
In a session from Tuesday, George Adams, MD, MHS, MBA, FACC, FSCAI, from UNC REX Hospital in Raleigh, North Carolina, presented results from the LIBERTY 360 analysis on patients with chronic limb-threatening ischemia. 
In a session from Tuesday, George Adams, MD, MHS, MBA, FACC, FSCAI, from UNC REX Hospital in Raleigh, North Carolina, presented results from the LIBERTY 360 analysis on patients with chronic limb-threatening ischemia. 
In a session from Tuesday,...
01/17/2023
Vascular Disease Management

Advertisement

Advertisement

Stay in the Know

Vascular Disease Management Newsletter

Advertisement

Advertisement

News

First Aid guidelines
AHA/American Red Cross: Updated First Aid Guidelines Enhance Care for Opioid Overdose, Bleeding, Other Emergencies
11/14/2024
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major...
11/14/2024
Cath Lab Digest
Late-Breaking Trials
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/06/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a...
11/06/2024
Vascular Disease Management
Late-Breaking Trials
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/05/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/05/2024
Vascular Disease Management
Late-Breaking Trials
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Late-Breaking Trials
First Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Image-Guided Therapy
Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease
11/04/2024
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first...
11/04/2024
Vascular Disease Management
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate...
11/04/2024
Vascular Disease Management
Peripheral Arterial Disease
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
11/04/2024
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November...
11/04/2024
Vascular Disease Management
Patient Awareness
Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases
10/31/2024
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in...
10/31/2024
Vascular Disease Management
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement